… $249.5 million in Q1; decline driven by limited … of our business in the first quarter, including strong international segment … definitive agreement to acquire Pillar5 Pharma Inc. (“Pillar5”), a … less cash paid for capital expenditures. Net Debt: Calculated …

Total revenue from continuing operations increased 9%; constant currency organic revenue grew 8% As reported EPS from continuing operations increased to $1.79; adjusted EPS increased to $2.34 Fiscal 2026 revenue and free cash flow outlook updated DUBLIN, …

… conclude by the end of Q1 2026 and an NDA … will support operations into the first quarter of 2026. Net Loss: … increase in research and development expenditure in the three and six … in 2024. About Quoin Pharmaceuticals Ltd. Quoin Pharmaceuticals Ltd. is a late …

… Aurora Cannabis Incorporated Fiscal First Quarter 2026 Results Conference Call … relationships with distributors and pharmacies and this provides an … financial overview of fiscal Q1 followed by a … capital and lower capital expenditures. Let me now provide …

While announced foreign direct investment (FDI) projects in the US have experienced substantial growth so far in 2025, capital expenditure (capex) has fallen and is projected to decrease further during the rest of the year, according to a new report. …

… end user, the pharmaceutical and biotechnology industry … 𝗞𝗲𝘆 𝗠𝗮𝗿𝗸𝗲𝘁 𝗣𝗹𝗮𝘆𝗲𝗿𝘀 𝗔𝗿𝗲 - • Dalton Pharma Service, • Curia Global Inc, • … increase in healthcare expenditure, and the presence … Africa) 𝗙𝗿𝗲𝗾𝘂𝗲𝗻𝘁𝗹𝘆 𝗔𝘀𝗸𝗲𝗱 𝗤𝘂𝗲𝘀𝘁𝗶𝗼𝗻𝘀? Q1. What are the upcoming …

… results for the first quarter of Fiscal year 2026 … crore in capital expenditure during Q1FY26 Business Highlights … that partners with innovator pharmaceutical and biotech companies to … regulations that apply to pharmaceuticals, increasing competition in …

 Aurobindo Pharma’s consolidated net profit … to ₹824 crore in the first quarter ended June 30, 2025 compared … revenue of the Hyderabad-based drug-maker, however, increased 4 per … (R&D including depreciation) expenditure was at ₹367 crore, amounting …

Sun Pharma Advanced Research Company (SPARC) reported … quarter ended June 30, 2025 (Q1 FY26), significantly narrowing from the … Rs 95.9 crore in Q1 FY25. However, the company … in Q1 FY25. The reduction in employee costs and clinical trial expenditure …

The final cohort of the single ascending dose (SAD) part of the Phase 1 AVALON trial initiated, with the SAD data readout expected early in the fourth quarter of 2025; The multiple ascending dose (MAD) part of the AVALON trial initiated; Available …